Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Inclusion Criteria: * Male and female subjects 18 to 55 years of age (inclusive) at time of informed consent * Subjects with a primary current Axis 1 disorder of bipolar 1 disorder or schizophrenia as defined by DSM-IV-TR criteria, who have been treated in the outpatient setting for at least 2 months before screening * Subjects with a score of 1-7 on the Morisky 8-Item Medication Adherence Scale (MMAS-8) * Subjects with bipolar 1 disorder who have a YMRS score of 10 to 25 (inclusive), or subjects with schizophrenia who have a PANSS score of 60 to 90 (inclusive) * Subjects able to ingest oral medication * Subjects currently prescribed oral aripiprazole for either bipolar 1 disorder or schizophrenia, and who have not had any changes in their Aripiprazole regimen or dose over the last 2 weeks * Subjects who have an exacerbation of mood or psychotic symptoms when they are not receiving treatment or are noncompliant with treatment for their bipolar 1 disorder or schizophrenia * For subjects enrolled with bipolar 1 disorder, the current bipolar episode is mixed or manic (the current must not be a depressive episode) Exclusion Criteria: * Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar 1 disorder or schizophrenia * Subjects with a current Axis II (DSM-IV-TR) diagnosis * Subjects not able to self-administer their medication * Subjects who reside in or attend a facility where medication is administered to them * Subjects who have a score of 0 or 8 on the Morisky 8-Item Medication Adherence Scale (MMAS-8) * Subjects who currently meet DSM-IV-TR criteria for substance dependence * Subjects with a history of inpatient hospitalization for any psychiatric reason within the past 2 months before screening * Subjects who have received any investigational product within the last 30 days * Subjects known to be allergic, intolerant, or unresponsive to prior treatment with Aripiprazole or other quinolinones * Subjects who, per investigator's judgment, are acutely psychotic or manic and/or exhibit symptoms currently requiring hospitalization